BHCM
PCVX icon

Brevan Howard Capital Management’s Vaxcyte PCVX Stock Holding History

Brevan Howard Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$984K Buy
16,935
+5,293
+45% +$287K 0.01% 1068
2026
Q1 		$677K Sell
11,642
-22,709
-66% -$1.23M 0.01% 1117
2025
Q4 		$1.58M Sell
34,351
-32,782
-49% -$1.47M 0.02% 570
2025
Q3 		$2.42M Buy
67,133
+12,138
+22% +$402K 0.01% 476
2025
Q2 		$1.79M Buy
+54,995
New +$1.8M 0.01% 787
2025
Q1 		– Sell
-4,393
Closed -$360K – 1383
2024
Q4 		$360K Buy
4,393
+2,546
+138% +$253K ﹤0.01% 725
2024
Q3 		$211K Buy
+1,847
New +$166K ﹤0.01% 980

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Brevan Howard Capital Management's PCVX Position: Q2 2026 in Review

Brevan Howard Capital Management increased its Vaxcyte (PCVX) stake by 45% in Q2 2026, buying an estimated $287K and bringing the position to 16,935 shares worth $984K. The position accounts for 0.01% of the portfolio, ranked #1068.

Brevan Howard Capital Management first reported a position in PCVX in Q3 2024 and has held it in 7 quarters since. The position peaked at $2.42M in Q3 2025. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Brevan Howard Capital Management held 16,935 shares of Vaxcyte worth $984K as of Q2 2026.
  • Brevan Howard Capital Management bought 5,293 Vaxcyte shares in Q2 2026, an estimated $287K.
  • Vaxcyte made up 0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1068 holding.
  • Brevan Howard Capital Management first reported a position in Vaxcyte in Q3 2024 and has held it in 7 quarters since.
  • Brevan Howard Capital Management's Vaxcyte position peaked at $2.42M in Q3 2025.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.